19:59 , Jul 27, 2018 |  BioCentury  |  Finance

Manipulating microglia

Alector Inc.’s $133 million series E round provides enough runway for the immuno-neurology and immuno-oncology company to take at least five programs into the clinic in the next two years. Participants in the untranched round,...
18:11 , Jul 27, 2018 |  BC Week In Review  |  Financial News

Alector raises $133M series E

Immuno-neurology and immuno-oncology company Alector Inc. (South San Francisco, Calif.) raised $133 million in a series E round. Participants included new investors Deerfield Management, Federated Kaufmann Fund, Section 32, Euclidean Capital, Foresite Capital, Lilly Asia Ventures,...
11:02 , Jul 25, 2018 |  BC Extra  |  Financial News

Alector raises $133M series E

Immuno-neurology and immuno-oncology company Alector Inc. (South San Francisco, Calif.) raised $133 million in a series E round. Participants included new investors Deerfield Management, Federated Kaufmann Fund, Section 32, Euclidean Capital, Foresite Capital, Lilly Asia Ventures,...